Uterine carcinosarcoma (UCS) is a malignant tumor with a high tendency to invasion and metastasis. However, the underlying invasion and metastasis mechanisms of UCS remain poorly understood. Genetic alteration and tumor-infiltrating immune cells play important roles in tumorigenesis, progression, and metastasis. To better understand the underlying mechanisms of UCS, we screened tumor-infiltrating immune cells by applying CIBERSORT algorithm and constructed nomograms to predict the prognosis of UCS patients based on metastasis-specific tumor-infiltrating immune cells and genes, and demonstrated their utility by the high AUC values. Combining gene co-expression and experimental validation results, we propose a potential mechanism of AK8, MPZ, and mast cells activated might play important parts in UCS metastasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s43032-021-00584-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GP73 reinforces cytotoxic T-cell function by regulating HIF-1α and increasing antitumor efficacy.
J Immunother Cancer
January 2025
Department of Clinical Laboratory, The Third Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China
Background: Immunotherapy that targets immune checkpoints has achieved revolutionary success, but its application in solid tumors remains limited, highlighting the need for reliable enhancement of the efficacy of immunotherapy. Golgi protein 73 (GP73), a Golgi membrane protein, has been implicated in various cellular processes, including immune regulation. Recent studies suggested that GP73 may play a role in modulating the immune response in patients with cancer.
View Article and Find Full Text PDFAnti-PD-1 amplifies costimulation in melanoma-infiltrating T1-like Foxp3 regulatory T cells to alleviate local immunosuppression.
J Immunother Cancer
January 2025
Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada
Background: Immune checkpoint inhibitors targeting programmed cell death protein-1 (PD-1) are the first line of treatment for many solid tumors including melanoma. PD-1 blockade enhances the effector functions of melanoma-infiltrating CD8 T cells, leading to durable tumor remissions. However, 55% of patients with melanoma do not respond to treatment.
View Article and Find Full Text PDFThe epitranscriptional factor PCIF1 orchestrates CD8 T cell ferroptosis and activation to control antitumor immunity.
Nat Immunol
January 2025
Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
T cell-based immunotherapies have revolutionized cancer treatment, yet durable responses remain elusive. Here we show that PCIF1, an RNA N 2'-O-dimethyladenosine (mA) methyltransferase, negatively regulates CD8 T cell antitumor responses. Whole-body or T cell-specific Pcif1 knockout (KO) reduced tumor growth in mice.
View Article and Find Full Text PDFTumor β-Catenin Expression Associated With Poor Prognosis to Anti-PD-1 Antibody Monotherapy in Non-small Cell Lung Cancer.
Cancer Diagn Progn
January 2025
Department of Chest Surgery, Fukushima Medical University, Fukushima, Japan.
Background/aim: Tumor intrinsic β-catenin signaling has been reported to influence the tumor immune microenvironment and may be a resistance mechanism to immune checkpoint inhibitors in various cancers.
Patients And Methods: We studied the association between tumor β-catenin expression and survival in 50 patients with non-small cell lung cancer (NSCLC) treated with anti-programmed death-1 antibody monotherapy. Tumor β-catenin expression was evaluated by immunohistochemistry.
IGF2-IGF1R signaling inhibition delays the growth of IGF2-high colorectal cancer by modulating MDSCs.
Biochem Biophys Res Commun
December 2024
Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China; Department of Oncology, PLA Rocket Force Characteristic Medical Center, Beijing, 100088, China. Electronic address:
Approximately 22 % of human colorectal cancers (CRC) are characterized by IGF2 overexpression, and the tumor-promoting role of IGF2 has been widely reported. Despite promising preclinical results, IGF2 signaling inhibition therapy has exhibited limited efficacy in treating unselected patients with CRC. Recent evidence suggests that IGF2-high CRC are more sensitive to IGF2 signaling blockade therapy in immune-deficient mice, suggesting that IGF2-high CRC can benefit from IGF2 signaling blockade therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!